
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is supported by a strong bezuclastinib data package, with the APEX trial showing a 65% ORR in AdvSM, 81% response by pathological criteria, and durable 12-month PFS/OS of 79%/87%, which underpins confidence in regulatory approval. The company also has multiple near-term catalysts, including FDA PDUFA dates for GIST on November 30, 2026, NonAdvSM on December 30, 2026, and AdvSM on June 29, 2027, creating a potentially transformative commercial run-rate across three indications. Financially, it ended 3Q26 with $791.1M in cash and equivalents and a projected runway into late 2028, while the modest 3Q26 net loss of $0.59 per share suggests sufficient balance-sheet strength to execute its pipeline.
Bears say
Cogent Biosciences is viewed negatively because AdvSM remains a competitive market, with Sanofi’s Ayvakit already established as the standard of care and physicians having substantial experience with an effective KIT inhibitor, making utilization gains difficult without heavy commercial spending. The company’s valuation is especially vulnerable to poorer-than-expected clinical results from CGT9486, which could force lower market penetration assumptions, higher discount rates, and a longer path to approval or even prevent approval entirely. Additional downside comes from the risk of stronger competitor products and broader regulatory and commercial execution challenges, leaving the investment case dependent on overcoming significant clinical and adoption hurdles.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cogent Biosciences, Inc. (COGT) Forecast
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares